Healthtech Late Stage Investors & VC Firms
847 firms in this list, with a median first check of $1M. 197 of them lead rounds. Generated from verified public data and updated continuously.
Ridgeback Capital
MiamiSeed–Late Stage
1 person
Alium Capital
SydneySeed–Late Stage
6 people
Kerala Ventures
ParisPre-Seed–Late Stage$108K – $1.1M
3 people
Legendary Ventures, Llc.
New York CitySeed–Late Stage
6 people
Martinson Ventures
PennsylvaniaGrowth–Late Stage$2M – $15M
3 people
NGN Capital
New YorkSeries A–Late Stage
6 people
Heron Capital
IndianapolisSeries A–Late Stage$10M
5 people
Applied Real Intelligence (A.R.I.)
Los AngelesSeries A–Late Stage$30M
6 people
Bering Capital
San FranciscoSeed–Late Stage
6 people
dsm-firmenich Venturing
MaastrichtPre-Seed–Late Stage$108K – $5.4M
9 people
EMBL Ventures
HeidelbergSeed–Late Stage$108K – $5.4M
LIP Ventures Boutique
Mexico CityLate Stage
SBI Investment Korea Co. Ltd.
SeoulSeed–Late Stage$2.5M – $33M
Claremont Creek Ventures
OaklandSeed–Late Stage$500K – $3M
4 people
Optimist Ventures
New YorkPre-Seed–Late Stage
4 people
Champel Capital
JerusalemSeed–Late Stage
5 people
Sanara Capital
Ra'ananaSeed–Late Stage
1 person
T. Rowe Price
BaltimoreSeed–Late Stage
1 person
Centurium Capital
XiamenGrowth–Late Stage
Xerys
ParisSeed–Late Stage$16M – $97M
Springboard Growth Capital
New YorkGrowth–Late Stage
5 people
What If Ventures
FriscoPre-Seed–Late Stage
1 person
Quad Ventures
SeoulPre-Seed–Late Stage
4 people
Southlight Capital
Mexico CitySeed–Late Stage
4 people
Related lists
Healthtech Investors & VC Firms (3208)Late Stage Investors & VC Firms (2864)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)Healthtech Series B Investors & VC Firms (1216)Healthtech Growth Investors & VC Firms (1213)Late Stage Investors & VC Firms in United States (1101)Late Stage Investors & VC Firms in Global (857)
Data sourced from public filings and firms' own websites — see our methodology.





























